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The novel anti-oestrogen idoxifene inhibits the growth
of human MCF-7 breast cancer xenografts and reduces
the frequency of acquired anti-oestrogen resistance
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Summary The effect of idoxifene, a novel anti-oestrogen with less agonist activity than tamoxifen, was compared with that of tamoxifen on
the growth of hormone-dependent MCF-7 breast cancer xenografts. Forty tumours were established with oestradiol support in ovariectomized
athymic mice, allowed to grow to a median volume of 420 mm3 and then continued with oestradiol, no support, tamoxifen or idoxifene
delivered by 1.5-cm silastic capsule. Tumour regression occurred with both anti-oestrogens, although maximum regression was observed
following oestradiol withdrawal alone. While prolonged anti-oestrogen therapy was associated with static growth, tumour volumes were
significantly lower with idoxifene (P=0.01). After 6 months, 0/10 idoxifene-treated tumours developed acquired resistance compared with 3/10
tumours treated with tamoxifen. In separate experiments, 94 animals were treated initially with oestradiol, tamoxifen, idoxifene or placebo
following implantation with 1-mm3 pieces of either wild-type (WT) or tamoxifen-resistant (TR) MCF-7 tumour. After 4 months, only 1/11 WT
tumours became established with idoxifene compared with 4/11 with tamoxifen, 8/12 with oestradiol and 0/12 with placebo. Likewise, fewer
TR tumours were supported by idoxifene (3/12) than by tamoxifen (8/12) or oestrogen (11/12). These data indicate that, compared with
tamoxifen, idoxifene shows reduced growth support of MCF-7 xenografts and may share only partial cross-resistance. Furthermore, the
development of acquired anti-oestrogen resistance may be reduced during long-term idoxifene therapy. The drug's reduced agonist activity
may, in part, explain these observations and indicate a preferable biochemical profile for breast cancer treatment.
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The anti-oestrogen tamoxifen is established as first-line endocrine
therapy for women with breast cancer. In advanced breast cancer, it
is most effective in oestrogen receptor (ER)-positive tumours
(McGuire, 1978). However, most tumours that respond eventually
develop acquired resistance and start to regrow. MCF-7 cells are an
ER-positive hormone-dependent human breast cancer cell line, and
an animal model using MCF-7 xenografts in athymic mice has been
developed by several groups to investigate the phenomenon of
acquired anti-oestrogen resistance (Osborne et al, 1985; Gottardis
et al, 1988). It has been demonstrated that resistant tumours often
become growth dependent on tamoxifen and can be stimulated by
the drug in a dose-dependent manner (Gottardis and Jordan, 1988).
This growth can be reversed by tamoxifen withdrawal or inhibited
by the 'pure' non-steroidal anti-oestrogen ICI 164,384 (Gottardis et
al, 1989). It has been suggested that the partial agonist activity of
tamoxifen or its metabolites may be responsible for the acquisition
oftamoxifen-stimulated growth.
Idoxifene is a novel anti-oestrogen that is structurally related to
tamoxifen (Figure 1) (McCague, 1986). Analogues oftamoxifen that
include an iodine atom at position 4 have been found to have
increased affinity for ER (McCague et al, 1989). Such compounds
cannotundergo glucuronidation via4-hydroxylation, which probably
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aids the excretion oftamoxifen (McCague et al, 1990a), and, unlike
trans-4-hydroxytamoxifen, they cannot isomerize to the cis isomer,
which has much weaker anti-oestrogenic properties for tamoxifen,
while retaining partial agonist activity (Murphy et al, 1990). In addi-
tion, substitution of the dimethylamino group on the side-chain of
tamoxifen by the pyrrolidine ring prevents conversion by the liver to
desmethyl and didesmethyl metabolites, which are the predominant
circulating metabolites oftamoxifen found in humans (Daniel et al,
1981; Jordan et al, 1983). Studies have confirmed that these struc-
tural modifications result in a compound that is metabolically more
stable than tamoxifen (McCague et al, 1990b; Haynes et al, 1991).
Idoxifene was more effective than tamoxifen at inhibiting MCF-7
cell growth and rat mammary tumour growth (Chander et al, 1991).
Furthermore, observations thatidoxifene has reducedagonistactivity
in the immature rat uterotrophic assay compared with tamoxifen
(Chander et al, 1991) suggest that the drug may have a preferable
biochemical profile for clinical use, and could be an effective anti-
oestrogen in circumstances in which tamoxifen's agonist activity is
predominant.
We established a xenograft model to investigate the growth-
suppressive activity of idoxifene in acquired tamoxifen-resistant
human breast cancer (MCF-7 cells). In particular, we wished to
compare in established hormone-dependent xenografts the growth
inhibition achieved with idoxifene with that observed with tamox-
ifen treatment or oestradiol withdrawal. In view of its reported
lower agonist activity, we wished to determine whether long-term
administration ofidoxifene would reduce ordelay the emergence of
acquired resistance, and whether tamoxifen-resistant tumours
wouldremain sensitive to idoxifene in cross-resistance experiments.
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Figure 1 Chemical structures of the anti-oestrogens tamoxifen and idoxifene
MATERIALS AND METHODS
Chemicals
The two anti-oestrogens used in this study were tamoxifen { {Z-
trans-1-{4-[2-(dimethylamino)ethoxy]phenyl)-1,2-diphenyl- 1-
butene}) from Sigma Chemical Co., Poole, UK, and idoxifene
{E-trans-1-(4-iodophenyl)-1-[4-(2-pyrrolidinoethoxy) phenyl]-2-
phenyl-1-butene) (McCague, 1986) synthesized at The Cancer
Research Campaign Centre for Cancer Therapeutics, Institute of
Cancer Research, Sutton, UK.
Drug delivery system
Slow-release silastic capsules of tamoxifen and idoxifene were
made according to previously published methods (Gottardis et al,
1989). Briefly, these were formed by plugging one end ofa 1.5-cm
length of medical-grade silastic tubing (0.078 inch internal diam-
eter by 0.125 inch outside diameter; Dow Coming, Midland, MI,
USA) with silastic 382 medical-grade adhesive. After drying,
these were filled with either tamoxifen free base or the crystalline
form ofidoxifene. Based on the relative molecular weight ofeach
drug (tamoxifen, 371.3; idoxifene, 497.4), an estimated molar
equivalent amount of each drug was put into each capsule (20 mg
oftamoxifen and 26 mg ofidoxifene per capsule), and the capsule
was sealed by plugging the open end with adhesive. All capsules
were sterilized by y-irradiation (200 Gy) before subcutaneous
implantation under general anaesthetic on the left dorsal
paraspinal area.
Serum drug levels
In preliminary experiments to establish the serum levels and phar-
macological profile of each drug, a total of 24 mice were
implanted along the left flank (parallel to the spine) with 1.5-cm
silastic capsules containing either tamoxifen or idoxifene. Four
mice from each group were sacrificed and bled at 2, 4 and between
6 and 8 weeks. The total serum level ofeachdrug was measured at
these time points by high-performance liquid chromatography
(HPLC) according to previously published methodology
(Johnston et al, 1993). The recovery from the mouse serum for
eachdrug was 97%, and the lower detection limit for the assay was
0.1 ng ml-' for tamoxifen and 0.2 ng ml-' for idoxifene.
Animals and tumours
MCF-7 xenografts were established from cells that had been
growing in culture in RPMI-1640 medium (Life Technologies,
Paisley, Strathclyde, UK) supplemented with 10% fetal calfserum
(Life Technologies.), 2 mM L-glutamine, 5 U ml-' penicillin, 5 mg
ml-' streptomycin and 12.5 ng ml-' amphotericin (Sigma Chemical
Co.). Cells were recovered from six 80% confluent 175-cm2 flasks
by scraping and were resuspended immediately in 2.5 ml of fresh
medium. Approximately 107 cells (0.2 ml) were injected in
suspension into the right flank of each of ten ovariectomized
athymic nude mice (ICRF nunw mice; Harlan, Oxford, UK). At
the same time, each mouse received a 1.7-mg 60-day release 17p-
oestrodiol (E2) pellet (Innovative Research of America, Toledo,
OH, USA) implanted under the neck skin under general anaes-
thesia. After 8-12 weeks, oestradiol-dependent wild-type (WT)
tumours were established for passage in subsequent experiments.
All procedures were approved by the Institute of Cancer Research
ethics committee.
Growth inhibition of MCF-7 xenografts
Forty mice were implanted with 1-mm3 pieces of WT tumour in
the right flank and supported with E2 pellets implanted at the same
time under general anaesthesia. Bidimensional tumour diameters
were measured by caliper at weekly intervals, and tumour volume
in cubic mm was estimated using the formula:
Tumour volume = (width)2 x length
2
At week 9, animals were randomly sorted into four groups of
ten, which were treated differently: (1) E2 support with 1.7-mg 60-
day release pellet continued; (2) E2 support withdrawn by removal
of pellet; (3) tamoxifen; or (4) idoxifene delivered by silastic
capsule as described above. In the last two groups, E2 support was
withdrawn at the same time as the anti-oestrogen capsule was
implanted. Tumour measurements were made weekly and change
in tumour size for each animal recorded as the percentage of the
baseline size reached at week 9. During prolonged treatment, drug
capsules were changed every 60 days under general anaesthesia.
The experiment was continued for 6 months to determine whether
any tumours would develop acquired resistance and start to
regrow.
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Table 1 Serum concentrations of tamoxifen and idoxifene achieved 2, 4 and
6 weeks after implantation of 1.5-cm silastic capsules filled with equimolar
amounts of tamoxifen and idoxifene
Duration of n Tamoxifen n Idoxifene
therapy (weeks) (ng mi-1) (ng ml-')
2 4 34.3±6.5 4 17.3± 1.2
4 3 36.7 ± 6.5 4 23.8 ± 4.2
6-8 4 29.5±5.4 3 25.3±2.2
Values are expressed in ng ml-' as means ± s.e. Detection limits were
tamoxifen (0.1 ng ml-') and idoxifene (0.2 ng ml-').
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Figure 2 Effect of tamoxifen, idoxifene or oestradiol withdrawal on growth of
MCF-7 xenografts in nude mice. All tumours were initially growth supported
with oestradiol. At week 9, capsules were changed to either continued
oestradiol, tamoxifen, idoxifene or placebo. Tumour volumes were measured
weekly and expressed as the percentage baseline volume at 9 weeks
(mean ± s.e.)
Growth support of WT and TR tumours
Another48 mice were implanted with 1-mm3 pieces ofWT tumour
in sequential duplicate experiments (24 mice per experiment). In
each experiment, four groups ofsix mice were supported from the
time of tumour implantation with either E2 pellet, placebo pellet,
tamoxifen capsule oridoxifene capsule foratotal of 16 weeks. The
pellets or capsules were replaced under general anaesthesia after 8
weeks. The WT tumour take rates (i.e. number of tumours that
become established by week 16) in each group and growth rate of
any established tumours were recorded.
In parallel experiments, a further 48 mice were implanted with
1-mm3 pieces from two tamoxifen-resistant (TR) tumours that had
developed acquired tamoxifen resistance during long-term tamox-
ifen treatment. The original E2-established WT tumours from these
two mice had regressed following tamoxifen therapy, but after 18
and 21 weeks, started to regrow despite continued tamoxifen. In a
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Figure 3 Growth rate of three MCF-7 xenografts that regrew during
prolonged tamoxifen therapy and developed acquired resistance. Tamoxifen
capsules were changed every 8 weeks as indicated by the arrows
similar design to the experiments with WT tumour, four groups of
six mice (repeated in duplicate) were supported with E2, placebo,
tamoxifen or idoxifene for 16 weeks, and the TR tumour take rate
and growth rate were recorded.
Statistics
Growth rates for individual tumours were calculated assuming an
exponential model within individual time segments. The growth
rate was calculated as the slope ofthe line oflog (volume) plotted
against time. Comparisons in growth rate were performed using
the Kruskal-Wallis one-way analysis of variance for the three
treatment groups (tamoxifen, idoxifene and placebo), with the
Mann-Whitney test for two samples using a multiple comparison
corrected P-value of0.017 (i.e. 0.05/3).
RESULTS
Serum tamoxifen and idoxifene concentrations
In preliminary experiments with 24 mice, the serum concentra-
tions of tamoxifen and idoxifene obtained using the slow-release
silastic capsules were measured after 2, 4 and 6 weeks. These data
are shown in Table 1. By 4 and 6 weeks when steady state would
be expected, the mean concentration of tamoxifen and idoxifene
was 35.3 ± 4.3 ng ml-' and 28.4 ± 2.2 ng ml', respectively, which
is equivalent to 95 nm for tamoxifen and 57 nm for idoxifene.
Growth inhibition of MCF-7 xenografts
Tumour size obtained after initial oestradiol support varied
markedly with the smallest tumour measuring 78 mm3 and the
largest 2790 mm3. However, the median tumour size and ranges in
each ofthe four groups often mice were similar(413, 342,434 and
366 mm3) such that valid comparisons in growth inhibition could
be made between groups.
Tumours treated with further E2 support continued to grow at a
steady rate. Tumours in which E2 support was withdrawn
regressed in size such that by week 26 the mean tumour size was
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and grew at rates similar to those observed with WT tumours,
whereas 0/12 tumours took when treated with placebo. More TR
tumours were supported by tamoxifen than by idoxifene (8/12 vs
3/12), although this was not statistically significant (P=0.0995,
Fisher's exact test, two-tail). No difference was observed between
the TR tumour growth rates in idoxifene and tamoxifen-treated
animals, although the median time to tumour take was longer with
idoxifene (9 weeks vs 5 weeks). Growth rates with both anti-
oestrogens were slower than with oestradiol (Figure 4).
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Figure 4 Effect of oestrogen, tamoxifen and idoxifene on the growth support
of tamoxifen-resistant (TR) MCF-7 xenografts. Tumour implants from an
acquired tamoxifen-resistant tumour (1 mm3 size) were implanted on day 0
into 48 mice that were then randomly allocated to receive oestradiol,
tamoxifen, idoxifene or placebo by silastic capsule (capsules replaced again
after 8 weeks). The weekly mean tumour volumes are displayed (± s.e.) for
the tumours that became established (take-rate indicated in brackets)
12% of baseline (Figure 2) and 3/10 tumours had regressed
completely. In mice treated with tamoxifen, tumour growth
continued initially and peaked at 112% at week 10. Thereafter,
tamoxifen induced tumour regression, although this was signifi-
cantly less than that observed following E2 withdrawal
(P=0.0003). Idoxifene induced immediate tumour regression that
was significantly greater than that in the tamoxifen-treated group
(P=0.01) (Figure 2).
During prolonged anti-oestrogen therapy, tumour volumes in
mice treated with tamoxifen remained static and 3/10 tumours
started to regrow after an interval of 15, 18 and 21 weeks of
therapy respectively. The growth of these individual tumours that
developed acquired tamoxifen resistance is shown in Figure 3. In
contrast, no tumours treated with idoxifene started to regrow
during this same time period.
Growth support of wild-type (WT) and tamoxifen-
resistant (TR) tumours
Two ofthe 96 animals (one tamoxifen WT and one idoxifene WT)
died shortly after tumour passage and capsule implantation
(necropsies were not performed). The remaining 94 animals were
observed for 16 weeks. WT tumour growth was dependent on E2
support, as 0/12 tumours grew with placebo compared with 8/12
treated with E2, these latter tumours arising after a median of 3
weeks. With tamoxifen, 4/11 tumours took after a median of 9
weeks, whereas only 1/11 WT tumours treated with idoxifene
became established (and then only at week 15).
The growth of TR tumours was also dependent on endocrine
support to become established; 11/12 E2-supported tumours took
DISCUSSION
MCF-7 xenografts established in ovariectomized nude mice and
treated with long-term tamoxifen provide a model for investi-
gating acquired anti-oestrogen resistance in breast cancer.
Previous studies have established that, while tamoxifen will cause
partial regression of established xenografts, continued administra-
tion is associated with static growth and stable tumour volumes
(Osborne et al, 1985; Gottardis et al, 1988). Following prolonged
therapy, resistance eventually develops in this model and tumours
regrow despite continued tamoxifen (Gottardis and Jordan, 1988).
Subsequent studies have shown these tumours to be growth-stimu-
lated by tamoxifen in a dose-dependent manner and that growth
can be reduced by withdrawal oftamoxifen (Gottardis et al, 1989).
In cross-resistance experiments, the pure anti-oestrogen, ICI
164,384, can inhibit tamoxifen-stimulated growth of these resis-
tant tumours (Gottardis et al, 1989), which implies a mechanism
for acquired resistance that is specific to tamoxifen. This mecha-
nism would explain the clinical observation that more than 50% of
patients with advanced breast cancer, who previously responded to
tamoxifen before developing acquired resistance, will respond to
further endocrine therapies with either pure anti-oestrogens
(Howell et al, 1995) or aromatase inhibitors (Dowsett et al, 1995).
Acquired tamoxifen resistance may be associated with the
agonist properties of the drug and/or its metabolites (Howell et al,
1990). Several of the known metabolites have more agonist than
antagonist effects. These include compounds formed following
metabolism of the dimethylamino side-chain (i.e. the monophenol
metabolite E and the bisphenol) (Lyman and Jordan, 1985).
Although the cis isomer of 4-hydroxytamoxifen is probably as
oestrogenic as the trans isomer, it is a much weaker antagonist
(McCague et al, 1990a). It has been suggested that a relative
increase within the tumour of more oestrogenic metabolites of
tamoxifen could stimulate growth (Osborne et al, 1991; Wiebe et
al, 1992). Analogues oftamoxifen in which the formation ofthese
metabolites is prevented or reduced may prove more effective
anti-oestrogens, and theoretically could delay the onset of any
acquired resistance that was caused by stimulation by agonist
metabolites.
Idoxifene is a structural analogue oftamoxifen that is metaboli-
cally more stable than tamoxifen. In vitro studies, using isolated
rat hepatocytes, demonstrated that idoxifene was metabolized
approximately three times more slowly than tamoxifen (Haynes et
al, 1991). In vivo idoxifene was shown to have a significantly
longer terminal half-life than tamoxifen in the rat (Haynes et al,
1991). In a recent phase I study in women with advanced breast
cancer (Coombes et al, 1995), the terminal half-life of idoxifene
was 3 weeks compared with a known half-life for tamoxifen of 7
days (DeVos et al, 1992). In addition, the antagonist/agonist
profile for idoxifene appears favourable to that for tamoxifen.
Idoxifene has a greater relative binding affinity (RBA) for the
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oestrogen receptor compared with tamoxifen (tamoxifen, 5; idox-
ifene, 12.5; oestradiol, 100) and is 1.5-fold more effective than
tamoxifen at inhibiting oestrogen-induced MCF-7 cell growth
(Chander et al, 1991). Idoxifene caused a greater percentage of
tumour regression in the hormone-dependent NMU-induced rat
mammary tumour model than tamoxifen (92% vs 75%). In
uterotrophic studies in immature rats and mice, idoxifene had
reduced agonist activity compared with tamoxifen in doses up to
10 mg kg-' (Chander et al, 1991). Overall, these data suggest that,
compared with tamoxifen, idoxifene is metabolically more stable,
has reduced agonist activity and inhibits hormone-dependent
tumour growth more effectively.
Our data demonstrate greater tumour inhibition by idoxifene of
MCF-7 xenografts compared with tamoxifen in vivo. Equimolar
amounts of each drug were delivered by slow-release silastic
capsule and resulted in relatively similar serum concentrations that
remained stable during the 8 weeks each capsule was implanted.
The slightly lower mean levels (57 nm vs 95 nM) could have
resulted from variation in the release characteristics through
silastic as a consequence of the idoxifene's different chemical
structure. Unlike oestrogen withdrawal in this model in which
tumour size diminished to 12% of baseline after 6 months, both
tamoxifen and idoxifene maintained static tumour volumes
following an initial period of tumour regression (Figure 2). The
biological basis for these stable volumes remains unclear.
Classical anti-oestrogens are thought to be cytostatic in action
inhibiting cell cycle progression through G, (Sutherland et al,
1983), and initial reduction in tumour volume may represent
increased cell loss and/or reduced cell proliferation owing to
antagonism of the mitogenic signal. The advantage of this MCF-7
animal model, namely anti-oestrogen therapy in oophorectomized
mice after removal of the oestradiol pellet, is that it allows the
inherent agonist activity of the two drugs to be evaluated in the
absence of endogeneous or exogenous oestradiol. The significant
difference in the baseline level at which tumour size was main-
tained between idoxifene and tamoxifen during long-term anti-
oestrogen therapy could reflect the different agonist profiles of the
two agents.
The acquisition of resistance following prolonged therapy was
seen only in tamoxifen-treated tumours. None of the idoxifene-
treated tumours regrew during the 6-month experiment, although
it is possible that with more prolonged therapy idoxifene-resistant
tumours would have developed. Similar experiments that
compared the effects of the pure anti-oestrogen, ICI 182,780, with
those of tamoxifen in the same MCF-7 xenograft model demon-
strated that the pure anti-oestrogen suppressed tumour growth for
twice as long as treatment with tamoxifen (Osborne et al, 1995).
Eventually, most tumours became resistant to ICI 182,780,
although these experiments were conducted for much longer (11
months) compared with the idoxifene studies. However, both
studies imply that more effective oestrogen antagonism using
drugs with reduced agonist activity may provide not only greater
inhibition of tumour growth than tamoxifen, but may delay the
onset of acquired resistance. Clearly, such a property would be
highly advantageous for a novel endocrine agent, if this were
translated in the clinic into prolonged time to disease progression.
Experiments in which tumour implants are growth supported
from the outset with either oestrogen or anti-oestrogen allow a
comparison of the tumorigenic potential of each drug to be made.
Fewer wild-type MCF-7 tumours were growth supported by idox-
ifene compared with tamoxifen, with a longer time to tumour
formation and reduction in tumour take-rate. Similar observations
have been reported with wild-type MCF-7 xenografts treated with
the pure anti-oestrogen, ICI 182,780, compared with tamoxifen
(Osborne et al 1995). These data support those from experiments
that study growth inhibition of established MCF-7 tumours and
suggest that anti-oestrogens with less agonist activity are less
likely to support tumour growth.
Tamoxifen-resistant (TR) tumours were growth supported by
tamoxifen, although this phenotype clearly remained hormone
dependent as illustrated by the lack of tumours that developed in
the absence of any exogenous hormone. Idoxifene-supported
tumours were less frequent and developed later after a median of
15 weeks compared with 9 weeks for tamoxifen. Although there
was no statistical difference in the growth rates of idoxifene- and
tamoxifen-supported TR tumours, the latter were still growing
actively at 16 weeks when the experiment was terminated (Figure
4). The emergerence of tumours later that grow more slowly may
represent greater sensitivity ofTR tumours to idoxifene. This could
be interpreted as a lack of partial cross-resistance between the two
anti-oestrogens, although the hormone dependence of these idox-
ifene-supported tumours was not examined in further serial trans-
plant experiments. However, when ICI 182,780-resistant tumours
developed after 11 months and were transplanted into new mice,
they were noted to have become completely endocrine independent
and grew in the absence of oestradiol (Osborne et al, 1995).
These data imply that novel anti-oestrogens, such as idoxifene
or ICI 182,780, may inhibit the growth of tamoxifen-resistant
tumours more effectively, a feature which could be related to the
drug's reduced agonist activity. If the formation of oestrogenic
metabolites were a significant mechanism for tamoxifen relapse,
then structural analogues in which their formation is prevented or
reduced could be more effective anti-oestrogens. However, recent
data from two separate groups have shown that using fixed-ring
derivatives of tamoxifen in which isomerization is inhibited (thus
preventing formation of the cis isomer of 4-hydroxytamoxifen),
growth stimulation of resistant tumours occurred to the same
extent as with tamoxifen itself (Wolf et al, 1993; Osborne et al,
1994). Furthermore, analogues, such as deoxytamoxifen (in which
cleavage of the dimethylamino side-chain is impaired, thus
reducing formation of the oestrogenic metabolite E or bisphenol),
nafoxidine and toremifene all stimulated tumour growth (Osborne
et al, 1994). Thus, the mechansism for tamoxifen-stimulated
growth in this model remains unclear. Nonetheless, these data
imply that the contribution of oestrogenic metabolites of tamox-
ifen in stimulating the growth of established acquired tamoxifen-
resistant tumours is probably low. However, it remains possible
that structural analogues of tamoxifen with substantially less
agonist activity are more effective at inhibiting the growth of
hormone-sensitive tumours, which, compared with tamoxifen,
may result in the delayed onset ofacquired resistance. Ifthis trans-
lated in the clinical setting into prolonged disease control in the
primary or adjuvant setting, this would represent a significant
advantage for idoxifene over tamoxifen, currently the first-line
endocrine therapy forbreast cancer.
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